Business context and reporting period
This is IsoRay, Inc.’s Form 10-Q for the quarter and six months ended December 31, 2012 (the second quarter of its fiscal year). The supplied metadata names Perspective Therapeutics, Inc.; that does not match the registrant identified in the filing and should be verified. IsoRay sells Cesium-131 brachytherapy products for prostate and other cancer applications, and the GliaSite Radiation Therapy System.
Financial performance and position
- Quarter revenue: Product sales were $975,457, down 21% from $1,228,655. Prostate sales fell 19%; GliaSite sales were negative $15,750 because of returned catheters. Lung sales rose 30%.
- Quarter profitability: Gross loss was $158,626, compared with gross profit of $198,898; gross margin was negative 16% versus positive 16%. Operating loss was $1,099,455 versus $792,051, and net loss applicable to common shareholders was $1,156,985 versus $631,403. Basic and diluted loss per share was $0.03 versus $0.02.
- Six-month results: Product sales were $2,031,689, down 17%. Gross loss was $179,051 (negative 9% margin), versus gross profit of $265,240 (11% margin). Operating loss was $2,222,261 versus $1,894,368; net loss applicable to common shareholders was $2,153,311 versus $1,736,285. Loss per share was $0.06 in both periods.
- Cash flow and liquidity: Six-month operating cash use was $1,512,996, up from $1,014,096. Investing cash use was $13,491; financing provided $3,294,479, principally from a July 2012 registered offering. Cash and equivalents at December 31 were $4,440,703, up from $2,672,711 at June 30. Management reported approximately $4.06 million cash and equivalents on February 5, 2013.
- Balance sheet: Total assets were $8,716,787 and total liabilities $1,694,322 at December 31. The filing reports no conventional borrowings; liabilities included a $240,000 warrant derivative liability and a $757,509 asset retirement obligation. The current ratio was approximately 8.2x, based on reported current assets and current liabilities.
- Equity and dilution: The July 2012 sale of 3,626,943 common shares generated $3,291,977 net proceeds. Common shares outstanding were 34,611,517 at February 6, 2013.
Material changes versus prior comparable periods
Sales declines in prostate brachytherapy drove lower total revenue; growth in non-prostate applications did not offset the decline. Cost of product sales rose 10% in the quarter and 2% for six months, contributing to the shift from gross profit to gross loss. Management attributed quarterly cost pressure partly to the absence of a temporary, non-recurring isotope price reduction received in the prior-year quarter. Six-month operating expenses declined overall, including lower R&D costs, but this was more than offset by lower sales and higher product costs. Six-month GliaSite revenue increased 32% to $45,054, though customer onboarding and required license approvals were slower than anticipated.
Outlook, commentary, and risks
- Management said February 5 cash of approximately $4.06 million was expected to fund operations and capital expenditures for at least 12 months, based on its assumptions. It anticipated less than $100,000 in capital expenditures in the second half of fiscal 2013 and approximately $200,000 of fiscal-year protocol expenses.
- Management aims to reach breakeven through increased sales, GliaSite adoption, expansion into additional applications, and cost control, but warned that profitability and revenue growth are not assured. It also stated that additional capital may be needed for protocols, marketing, staffing, and equipment; financing could be unavailable or dilutive, and operations may need to be curtailed if funds cannot be raised.
- The company reported continued prostate-market pressure from competing treatments and noted that adoption of new applications depends on clinical experience, publications, medical-facility processes, and regulatory approvals. It cited a Russian isotope supplier outage in 2011 as having required inventory buildup.
- IsoRay warned it could fall below NYSE MKT minimum stockholders’ equity requirements for the quarter ending June 30, 2013 if it does not raise additional capital, creating a delisting risk.
- Disclosure controls were assessed as effective, but remediation of a material weakness and significant deficiency identified in the prior Form 10-K was still in progress. The company had added a CPA and planned further training and reviews.
- Other disclosed matters include environmental and radioactive-material obligations, product-liability exposure, and a related-party service arrangement with a company owned by the CEO. The filing states there were no off-balance-sheet arrangements.
Important facts for investors to verify
- Confirm the issuer and period: the filing is for IsoRay, Inc., not the company named in the request metadata.
- Review subsequent revenue, gross margins, and cash burn, particularly whether non-prostate and GliaSite sales can offset declining prostate sales.
- Check financing needs, dilution, cash runway, and compliance with NYSE MKT stockholders’ equity requirements.
- Track GliaSite adoption and facility nuclear-material license approvals, along with the progress and outcomes of protocol studies.
- Review the prior Form 10-K’s control findings and whether the remediation plan was completed.